AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$MAZE

Dandekar Atul sold $207K of MAZE

Dandekar Atul (CSBO) sold 7,500 shares of Maze Therapeutics, Inc. (MAZE) at $27.58 ($0.21M total) on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dandekar Atul
Published Aug 31, 2026, 10:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MAZE
Neutral
high confidence
Mentioned
$MAZE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAZENeutralLow
01

Why it matters

The transaction is routine and unlikely to affect the stock price.

02

Market read

Low relevance; typical insider sale with minimal market impact.

03

What to watch

Potential upcoming clinical data could make the insider's remaining position more relevant.

Relevance 3/10Novelty 2/10Timing: post‑market 2026‑08‑28

Background

Form 4 filing reports an insider's open‑market sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$MAZENeutralHigh confidence
Context

Officer Dandekar Atul sold 7,500 shares for $206,824 via a 10b5‑1 plan, reducing his stake to 26,250 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The sale size (~$0.2M) is small relative to market cap and follows a pre‑arranged plan.

Market effects

Sector

None; insider sale does not affect biotech sector broadly.

Regional

None; limited to US market.

Global

None

Counterpoint

What could challenge this read

The sale could signal insider confidence if the remaining stake is still sizable.

Key entities

  • company
    Maze Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • insider
    Dandekar Atul

    Chief Strategy and Business Officer at Maze Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAZE insider trading history →

Related articles

SEP 23
$MAZEHigh

Why is Maze Therapeutics stock climbing today?

Maze Therapeutics (MAZE) stock rose 2.9% in pre-market trading after CIBC initiated coverage with an Outperformer rating and a $50 price target. The company has 13 buy-equivalent ratings. Vertex Pharmaceuticals' (VRTX) positive kidney disease data also boosted MAZE, as both companies work on APOL1 inhibitors. The S&P 500, Dow, and Nasdaq showed little movement, indicating the rally was driven by company-specific news.

investing.com1 min
SEP 22
$VRTXMedAI 8/10

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder

Vertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.

newsable.asianetnews.com2 min
AUG 11
$MAZEMed

Maze Therapeutics, Inc. (MAZE): Results of Operations and Financial Condition

Maze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongo

SEC EDGAR 8-K4 min